Companion diagnostics is the use of specific tests whose results are linked to a particular drug. It allows clinicians the ability to better target the mechanism of pathology in the patient and follow it up with a therapy specifically designed to treat the disease process at hand. This approach to medicine has particularly been championed in the field of oncology with the development of such drugs as Zelboraf for the treatment of metastatic melanoma with the BRAFV600 mutation or Xalkori for late stage lung cancer expressing an abnormal ALK protein. In the case of non-small cell lung cancer (NSCLC) Jefferson has developed an algorithm to establish if patients are positive for mutations of EGFR or alterations of ALK, ROS1, or RET genes in which case patients can be treated with drugs such as erlotinib, crizotinib, and cabozantinib.
Recommended CitationBange, Erin and Bajaj, MS, PhD, CG (ASCP), CM, FACMG, Renu, "Molecular Profiling of Patients with Non Small Cell Lung Cancer at Jefferson University Hospital" (2014). Pathology Honors Program Student Research Symposium. Poster 25.